下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

针对 Dickkopf-1-A2 复合物工程化的 T 细胞可用于治疗 HLA-A2(+) 实体瘤和血液系统肿瘤

T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2(+) solid and hematologic cancers.

靶向 PIM2 通过促进 CD8 T 细胞的效应功能和持久性增强抗肿瘤免疫

Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.

平行处理 T 细胞与 NK 细胞以增强体内 CAR-T 细胞对血液肿瘤和实体瘤的活性

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

本研究鼓励优化利用白细胞单采产物。通过将废弃的 PBMC 回收为 NK 细胞，可有效增强 CAR-T 细胞疗法，改善肿瘤清除率和生存率。

通过定向进化改造靶向程序性死亡配体 1 的单体蛋白用于 SynNotch 门控细胞治疗

Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.

IGM-7354，一种将 IL15 与抗 PD-L1 IgM 融合的免疫细胞因子，可诱导 NK 和 CD8+ T 细胞介导的对 PD-L1 阳性肿瘤细胞的细胞毒性

IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor Cells.

靶向癌症干细胞的 CAR 免疫疗法：生物学、证据和未来方向

Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions.

CAR-T 细胞 K+ 通道在肿瘤浸润与清除中的作用

Role of CAR-T cell K+ channels in tumor infiltration and elimination.

结直肠癌和浸润性乳腺癌中 CAR-T 细胞治疗的临床新视角与挑战

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.

CAR-T 细胞对改造实体瘤细胞系的细胞毒性评估

Evaluation of CAR-T Cells' Cytotoxicity against Modified Solid Tumor Cell Lines.